ПОИСК ПО САЙТУ 
поиск по ресурсному центру 
Mylan wants to capture chronic Hep B market
The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection here, Mylan added.
входит в структуру портала 